Related Experiment Video
Updated: Apr 12, 2026
An Open-Source Normothermic Perfusion System Designed for Research Scientists
Published on: July 18, 2025
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic
Paul J Martin1, Stephanie J Lee1, Donna Przepiorka2
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract:
Treatment of chronic graft-versus-host disease is intended to produce a sustainable benefit by reducing symptom burden, controlling objective manifestations of disease activity, preventing damage and impairment, and improving overall survival without causing disproportionate harms related to the treatment itself. Successful management can control the disease until systemic treatment is no longer needed. The complexity of the disease, the extended duration of follow-up needed to observe disease resolution and withdrawal of immunosuppressive treatment, and the lack of fully developed shorter term endpoints impede progress in the field. Identification and characterization of primary endpoints demonstrating clinical benefit without requiring years of follow-up is urgently needed, with the understanding that clinical benefit encompasses not only the self-evident benefit of the primary endpoint but also any other associated benefits. This report discusses regulatory considerations, eligibility criteria, the value of controlled trial designs, the merits of proposed primary endpoints, and key considerations elaborated from experience and progress during the past decade. The report concludes by mapping an overall approach that could support and lead to maximally informative clinical trials, especially those that seek to demonstrate clinical benefit along a pathway to regulatory review and approval.
Insights
Developing effective treatments for chronic graft-versus-host disease (cGVHD) requires better clinical trial endpoints. New strategies are needed to demonstrate sustainable patient benefit and guide regulatory approval.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic graft-versus-host disease (cGVHD) management aims for long-term patient benefit, including symptom reduction and improved survival.
- Current treatment goals focus on disease control until immunosuppression withdrawal is possible.
- Disease complexity and lengthy follow-up periods hinder therapeutic progress.
Observation:
- Assessing treatment efficacy in cGVHD is challenging due to the need for extended observation periods.
- The lack of validated short-term endpoints complicates the evaluation of new therapies.
- Clinical benefit must encompass primary endpoint achievement and associated advantages.
Findings:
- This report reviews regulatory considerations, trial designs, and primary endpoint proposals for cGVHD studies.
- It emphasizes the need for endpoints that demonstrate clinical benefit without prolonged follow-up.
- Experience over the past decade informs key considerations for trial design.
Implications:
- Developing novel, shorter-term endpoints is crucial for advancing cGVHD research.
- Informative clinical trials are essential for regulatory review and approval of new treatments.
- A structured approach can lead to more efficient and impactful cGVHD clinical trials.
